Hu Tianyuan, Li Cong, Zhang Yingchi, Wang Le, Peng Luyun, Cheng Hui, Wang Weili, Chu Yajing, Xu Mingjiang, Cheng Tao, Yuan Weiping
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China.
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Biochem Biophys Res Commun. 2015 Apr 17;459(4):692-8. doi: 10.1016/j.bbrc.2015.03.007. Epub 2015 Mar 11.
Although great efforts have been made to improve available therapies, the mortality rate of acute myeloid leukemia (AML) remains high due to poor treatment response and frequent relapse after chemotherapy. Leukemia stem cells (LSCs) are thought to account for this poor prognosis and relapse. Phosphoinositide-dependent kinase 1 (PDK1) is a critical regulator of the PI3K/Akt pathway and has been shown to be frequently activated in leukemia. However, the role of PDK1 in the regulation of LSCs in AML is still not clear. Using a PDK1 conditional deletion MLL-AF9 murine AML model, we revealed that the deletion of PDK1 prolonged the survival of AML mice by inducing LSC apoptosis. This was accompanied by the increased expression of the pro-apoptotic genes Bax and p53 and the reduced expression of Stat5, which has been shown to be constitutively activated in leukemia. Thus, our findings suggest that PDK1 plays an essential role in maintaining LSCs. Further delineating the function of PDK1 in LSCs may provide a new strategy for the improved treatment of AML relapse.
尽管已经做出了巨大努力来改进现有的治疗方法,但由于治疗反应不佳以及化疗后频繁复发,急性髓系白血病(AML)的死亡率仍然很高。白血病干细胞(LSCs)被认为是导致这种不良预后和复发的原因。磷酸肌醇依赖性激酶1(PDK1)是PI3K/Akt通路的关键调节因子,并且已被证明在白血病中经常被激活。然而,PDK1在AML中对LSCs的调节作用仍不清楚。使用PDK1条件性缺失的MLL-AF9小鼠AML模型,我们发现PDK1的缺失通过诱导LSC凋亡延长了AML小鼠的生存期。这伴随着促凋亡基因Bax和p53表达的增加以及Stat5表达的减少,Stat5已被证明在白血病中持续激活。因此,我们的研究结果表明PDK1在维持LSCs中起重要作用。进一步阐明PDK1在LSCs中的功能可能为改善AML复发的治疗提供新策略。